Profile of Daniel Herranz, Principle Investigator


Daniel Herranz, PharmD, PhDDaniel Herranz, PharmD, PhD, is Assistant Professor of Pharmacology at Rutgers University. Over the last 10 years, Dr. Herranz has pursued a combined training in metabolism, epigenetics and how both affect human cancer development through the generation and analysis of relevant mouse models. After obtaining his training in Pharmacy from the Complutense University of Madrid, Dr. Herranz completed a PhD in Molecular Biology and Biochemistry from the Autonomous University of Madrid under the supervision of Dr. Manuel Serrano at the Spanish National Cancer Research Center (CNIO). Under his supervision, Dr. Herranz addressed the role of Sirt1 in metabolism, cancer and aging. Specifically, he demonstrated for the first time the protective role of Sirt1 from high-fat diet-induced metabolic damage (Pfluger*, Herranz* et al., PNAS, 2008) as well as from spontaneous aging-associated cancers and high-fat diet promoted liver cancers thereby increasing the healthspan of mice (Herranz et al, Nature Communications, 2010).

After completing his PhD, Dr. Herranz joined the laboratory of Adolfo Ferrando at Columbia University in April 2011 as a Postdoctoral Fellow. During his postdoctoral studies, Dr. Herranz uncovered N-Me as the long-sought missing link in the regulation of MYC by NOTCH1 in T-cells. As such, N-Me is a T-cell specific Myc oncogenic enhancer controlled by Notch1 that is critically required for normal T-cell development and for NOTCH1-induced T-ALL generation and maintenance (Herranz et al, Nature Medicine, 2014). Moreover, Dr. Herranz’s research unveiled that metabolic reprogramming after loss of the PTEN tumor suppressor gene can drive resistance to NOTCH1 inhibition in vivo and revealed a prominent role of glutaminolysis in NOTCH1-driven T-ALL, opening new therapeutic avenues (Herranz et al, Nature Medicine, 2015).

Dr. Herranz is currently an Assistant Professor in the Department of Pharmacology at the Robert Wood Johnson Medical School and a Resident Member at Rutgers Cancer Institute of New Jersey. His research on leukemia, Notch1 signaling and enhancer regions is currently funded by the National Cancer Institute (R00CA197869).

 

 

precision medicine at Rutgers Cancer Institute

 

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health